These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16338836)

  • 1. The use of piperacillin/tazobactam (in association with amikacin) in neonatal sepsis: efficacy and safety data.
    Flidel-Rimon O; Friedman S; Leibovitz E; Shinwell ES
    Scand J Infect Dis; 2006; 38(1):36-42. PubMed ID: 16338836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monotherapy with amikacin or piperacillin-tazobactum empirically in neonates at risk for early-onset sepsis: a randomized controlled trial.
    Tewari VV; Jain N
    J Trop Pediatr; 2014 Aug; 60(4):297-302. PubMed ID: 24699298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.
    Zengin E; Sarper N; Kılıç SC
    Pediatr Hematol Oncol; 2011 May; 28(4):311-20. PubMed ID: 21524156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Rizal AM; Nordiah AJ; Jamal R
    Singapore Med J; 2008 Jan; 49(1):26-30. PubMed ID: 18204765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver transplantation.
    Philpott-Howard J; Burroughs A; Fisher N; Hastings M; Kibbler C; Mutimer D; Patch D; Rolando N; Wade J; Wendon J; O'Grady J
    J Antimicrob Chemother; 2003 Dec; 52(6):993-1000. PubMed ID: 14585863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial using piperacillin versus ampicillin and amikacin for treatment of premature neonates with risk factors for sepsis.
    Hammerberg O; Kurnitzki C; Watts J; Rosenbloom D
    Eur J Clin Microbiol Infect Dis; 1989 Mar; 8(3):241-4. PubMed ID: 2496993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of piperacillin and tazobactam combination against clinically significant bacteria.
    Obi CL; Makandiramba B; Robertson V; Tswana SA; Moyo SR; Nziramasanga P
    East Afr Med J; 1998 Mar; 75(3):162-5. PubMed ID: 9640815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety evaluation of piperacillin/tazobactam in very low birth weight infants.
    Berger A; Kretzer V; Apfalter P; Rohrmeister K; Zaknun D; Pollak A
    J Chemother; 2004 Apr; 16(2):166-71. PubMed ID: 15216952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy.
    Flidel-Rimon O; Friedman S; Gradstein S; Bardenstein R; Shinwell ES
    Acta Paediatr; 2003 Oct; 92(10):1205-7. PubMed ID: 14632339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Piperacilline/tazobactam combination+amikacin versus ceftazidime+amikacin in patients with neutropenia and fever. An open multicenter study. Groupe d'étude des Aplasies Fébriles].
    Marie JP; Vekhoff A; Cony-Makhoul P; Fière D; Guy H; Herbrecht R; Milpied N; Pico JL; Plantier I
    Presse Med; 1995 Feb; 24(8):397-401. PubMed ID: 7899419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study.
    Adam HJ; DeCorby M; Rennie R; Karlowsky JA; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):307-13. PubMed ID: 21353958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of piperacillin/tazobactam as empirical monotherapy in the treatment of bacterial infections in a resuscitation department].
    Iakovlev SV; Shakhova TV; Dvoretskiĭ LI; Romanovskiĭ IuIa; Eremina LV; Koroleva TA; Orlova EA; Zhulin SL; Kaĭnov MS
    Antibiot Khimioter; 1997; 42(2):33-7. PubMed ID: 9124991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing epidemiology and resistance patterns of pathogens causing neonatal bacteremia.
    Mintz A; Mor M; Klinger G; Scheuerman O; Pirogovsky A; Sokolover N; Bromiker R
    Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1879-1884. PubMed ID: 32415489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin/tazobactam in the treatment of community-acquired and nosocomial respiratory tract infections: a review.
    Sanders CV
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S21-6. PubMed ID: 7962985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A combined dosage form of piperacillin and tazobactam--tazocin].
    Iakovlev SV
    Antibiot Khimioter; 1997; 42(2):5-16. PubMed ID: 9124994
    [No Abstract]   [Full Text] [Related]  

  • 20. Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols.
    Greenberg D; Moser A; Yagupsky P; Peled N; Hofman Y; Kapelushnik J; Leibovitz E
    Int J Antimicrob Agents; 2005 Jun; 25(6):469-73. PubMed ID: 15890499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.